Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05020678 · ClinicalTrials.gov registry record · Phase 1
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
A Phase 1 study of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma, sponsored by Nkarta.
- Active
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 6
- Study locations
NCT05020678: Active Phase 1 study of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma, sponsored by Nkarta.
NCT05020678 is a Phase 1 study of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma that is active but no longer recruiting, run by Nkarta. The registered enrollment target is 150 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (17% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05020678, a Phase 1 study of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma, is active but no longer recruiting, sponsored by Nkarta.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)
Primary Outcome
Incidence, nature, and severity of treatment related adverse events will be evaluated. An adverse event is any unfavorable and unintended sign including clinically significant abnormal laboratory findings, symptom or disease.
Conditions Studied
Interventions
- BIOLOGICAL NKX019
Study Locations (6)
New South Wales
- Institute of Haematology, Royal Prince Alfred Hospital - Camperdown
- St. Vincent's Hospital - Sydney
Colorado
- Colorado Blood Cancer Institute - Denver
Ohio
- The Cleveland Clinic Foundation - Cleveland
Queensland
- Royal Brisbane and Woman's Hospital - Brisbane
Victoria
- Peter MacCallum Cancer Center - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2021-08-20 |
| Est. Completion | 2038-12 |
| Phase | Phase 1 |
What the registry record for NCT05020678 still lists
NCT05020678 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (17% lower).
The record links to 10 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which NKX019 is the first listed.
NCT05020678 lists 6 locations in 5 states (New South Wales, Colorado, Ohio).
Frequently Asked Questions
What is clinical trial NCT05020678 about?
NCT05020678 is a clinical study titled "NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers". This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute...
What is the current status of trial NCT05020678?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2021-08-20. Estimated completion is 2038-12.
What conditions does trial NCT05020678 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia.
What interventions are being tested in trial NCT05020678?
The interventions under investigation include: NKX019 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05020678?
This trial is sponsored by Nkarta, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05020678 being conducted?
This trial has 6 study locations across Colorado, Ohio, New South Wales, Queensland, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05020678's enrollment target sits among peer trials
150 51st of 187 higher than 135 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI